Post Profile

AbbVie reports two patient deaths in rheumatoid arthritis study

(Reuters) - AbbVie Inc said on Monday two patients died in a late-stage trial testing its drug to treat patients with moderate to severe rheumatoid arthritis.
read more


Related Posts

Novartis says biosimilar rituximab accepted for review by FDA

Health : Reuters: Health

ZURICH (Reuters) - Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).

Sage's seizure drug fails key trial, shares slump

Health : Reuters: Health

(Reuters) - Sage Therapeutics Inc's shares tumbled 23 percent on Tuesday after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial, raising concerns about the future of the study.

Cimzia® (Certolizumab Pegol) Data Showed Rapid Improvement In Rheumatoid Arthritis Patients

Health : Medical News Today

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis (RA) patients treated with Cimzia® (certolizumab pegol),...

AbbVie's rheumatoid arthritis drug succeeds in late-stage trial

Health : Reuters: Health

(Reuters) - U.S. drugmaker AbbVie Inc said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to st...

AbbVie says deaths in arthritis trial not linked to drug

Health : Reuters: Health

(Reuters) - AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.


Copyright © 2016 Regator, LLC